-
1 Comment
Myomo, Inc is currently in a long term uptrend where the price is trading 2.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Myomo, Inc's total revenue rose by 149.2% to $4M since the same quarter in the previous year.
Its net income has increased by 38.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 56.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Myomo, Inc gets an overall score of 5/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | NYSE MKT |
CurrencyCode | USD |
ISIN | US62857J2015 |
Market Cap | 176M |
---|---|
PE Ratio | None |
Target Price | 9.25 |
Beta | 1.63 |
Dividend Yield | None |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MYO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025